迈得医疗(688310) - 2023 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2023 reached ¥132,256,078.13, representing a year-on-year increase of 105.89%[5] - The net profit attributable to shareholders for Q3 2023 was ¥31,891,916.46, a significant increase of 265.95% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2023 was ¥29,431,821.53, reflecting a remarkable growth of 503.78% year-on-year[5] - Total operating revenue for the first three quarters of 2023 reached ¥329,920,089.50, a significant increase from ¥197,458,228.88 in the same period of 2022, representing a growth of approximately 67%[20] - Net profit for the third quarter of 2023 was ¥81,881,942.77, up from ¥19,924,085.82 in the same quarter of 2022, reflecting a growth of over 311%[22] - The company reported a total comprehensive income of ¥81,731,356.05 for the third quarter of 2023, compared to ¥20,053,137.13 in the same quarter of 2022, reflecting an increase of over 307%[23] Earnings and Shareholder Value - The basic earnings per share for Q3 2023 was ¥0.27, an increase of 170.00% compared to the same period last year[6] - Basic earnings per share for the third quarter of 2023 was ¥0.61, compared to ¥0.23 in the same quarter of 2022, marking an increase of approximately 165%[23] - Total equity attributable to shareholders reached ¥859,296,464.08, compared to ¥819,185,766.28 in the previous year, indicating a growth of about 5%[18] Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥1,166,174,774.63, showing a 12.32% increase from the end of the previous year[6] - As of September 30, 2023, the total assets of the company amounted to RMB 1,166,174,774.63, an increase from RMB 1,038,263,199.72 as of December 31, 2022, reflecting a growth of approximately 12.3%[16] - The company's total liabilities as of the end of the third quarter of 2023 amounted to ¥260,151,997.52, up from ¥208,658,267.53 at the end of the previous year, representing an increase of approximately 25%[18] - The company's total current liabilities were RMB 244,840,023.71, up from RMB 193,087,243.69, reflecting an increase of approximately 26.7%[17] Cash Flow - The cash flow from operating activities for the year-to-date period reached ¥83,692,990.05, marking an increase of 108.32% compared to the same period last year[6] - Cash inflow from operating activities for the first three quarters of 2023 totaled ¥430,501,605.78, compared to ¥230,889,683.76 in the same period of 2022, showing an increase of about 87%[25] - The net cash flow from operating activities for Q3 2023 was $83,692,990.05, an increase from $40,175,806.98 in Q3 2022, representing a growth of 108%[26] - The total cash outflow from operating activities amounted to $346,808,615.73, compared to $190,713,876.78 in the same period last year, indicating a rise of 82%[26] Research and Development - Research and development expenses totaled ¥12,383,307.57 for Q3 2023, which is a 49.38% increase year-on-year[6] - Research and development expenses for the third quarter of 2023 were ¥26,700,469.34, slightly down from ¥26,912,034.42 in the same quarter of 2022, indicating a decrease of about 1%[21] Future Outlook and Strategy - The company plans to continue its focus on technological innovation and market development to sustain growth and enhance competitiveness[10] - The company has not provided specific future guidance or market expansion strategies in the current report[15] Other Financial Metrics - The weighted average return on net assets increased to 3.79%, up by 2.64 percentage points from the previous year[6] - The company's cash and cash equivalents reached RMB 270,668,184.93, up from RMB 224,946,034.81 at the end of 2022, indicating an increase of about 20.4%[16] - Accounts receivable increased to RMB 148,352,532.38 from RMB 121,053,391.62, representing a growth of approximately 22.5%[16] - Inventory levels rose significantly to RMB 187,928,215.57, compared to RMB 116,579,561.59 at the end of 2022, marking an increase of around 60.9%[16] - The company reported a significant increase in contract liabilities, which rose to RMB 85,581,059.90 from RMB 60,047,730.38, representing an increase of approximately 42.5%[17]